A federal judge in Illinois allowed a class action against Biogen Inc. to advance over the drugmaker’s alleged collusion with pharmacy benefit managers to favor its multiple sclerosis drug Tecfidera ...
The European Commission has approved dimethyl fumarate (Tecfidera, Biogen Idec) as a first-line oral treatment in relapsing-remitting multiple sclerosis (MS), the company reported today. Dimethyl ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results